Capital World Investors reports 0.5% Exact Sciences (EXAS) stake in 13G/A
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Exact Sciences Corp. received an updated ownership report from Capital World Investors, a division of Capital Research and Management Company and its affiliates. Capital World Investors is deemed to beneficially own 968,232 shares of Exact Sciences common stock, representing 0.5% of the 189,916,880 shares believed to be outstanding as of the reporting date.
The filing states that Capital World Investors has sole voting power over 968,142 shares and sole dispositive power over 968,232 shares, with no shared voting or dispositive power. It also certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Exact Sciences.
Positive
- None.
Negative
- None.
FAQ
What ownership stake does Capital World Investors report in Exact Sciences (EXAS)?
Capital World Investors reports beneficial ownership of 968,232 shares of Exact Sciences common stock, representing 0.5% of the 189,916,880 shares believed to be outstanding. This reflects a relatively small, passive institutional stake in EXAS.
Does Capital World Investors claim control intent over Exact Sciences (EXAS)?
No. Capital World Investors certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Exact Sciences, nor in connection with any transaction intended to have that effect.
Why did Capital World Investors file this Schedule 13G/A for Exact Sciences (EXAS)?
The Schedule 13G/A reports Capital World Investors’ beneficial ownership of Exact Sciences common stock as of 12/31/2025. The amendment updates its holdings and confirms they are held passively, without intent to change or influence control of the company.
What does ‘ownership of 5 percent or less of a class’ mean for EXAS in this filing?
Item 5 notes that Capital World Investors holds 5 percent or less of Exact Sciences’ common stock. Specifically, it reports a 0.5% stake, indicating a relatively small institutional position compared with the company’s total shares outstanding.